Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Velaglucerase Alfa in Chinese Subjects With Type 1 Gaucher Disease
NCT05529992Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2023
- Primary completion
- Aug 2024
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of velaglucerase alfa in Gaucher disease type 1 (GD1), sponsored by Takeda. Started Jan 2023; status: completed.
02
Drugs
velaglucerase alfa
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on NCT05529992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05529992.